Evidence map›Paper›PMID 31689387›Full record

ArticleNeuroscience2019

Cre-inducible Adeno Associated Virus-mediated Expression of P301L Mutant Tau Causes Motor Deficits and Neuronal Degeneration in the Substantia Nigra.

Yang You, Mina B Botros, Alicia A Van Enoo, Aaron Bockmiller, Shawn Herron, Jean Christophe Delpech, Tsuneya Ikezu

Open access · greenAbstract read
In one paragraph

Article in Neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yang YouDepartment of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA. Electronic address: yangyo91@bu.edu.
Mina B BotrosDepartment of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA. Electronic address: botrosm@bu.edu.
Alicia A Van EnooDepartment of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA. Electronic address: avanenoo@ucsd.edu.
Aaron BockmillerDepartment of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA. Electronic address: aaronbo@bu.edu.
Shawn HerronDepartment of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA. Electronic address: sherron@bu.edu.
Jean Christophe DelpechDepartment of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA. Electronic address: jdelpech@bu.edu.
Tsuneya IkezuDepartment of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA; Department of Neurology, Boston University School of Medicine, Boston, MA, USA; Center for Systems Neuroscience, Boston University, Boston, MA. Electronic address: tikezu@bu.edu.
Boston University · US

Funding

TRAINING IN BIOMOLECULAR PHARMACOLOGYT32GM008541 · NIGMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FARB, DAVID H · 1997 to 2022
$5.2M
Exosome-mediated propagation of pathogenic tau proteinRF1AG054199 · NIA · MAYO CLINIC JACKSONVILLE · PI IKEZU, TSUNEYA · 2016 to 2021
$5.0M
Targeting the miR-155 and APOE-TREM2 pathways to restore dysfunctional microglia in Alzheimer’s diseaseR01AG054672 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI BUTOVSKY, OLEG, IKEZU, TSUNEYA · 2017 to 2021
$4.1M
Biogenesis of Exosomes, Secretion, and Trafficking in Alzheimer's DiseaseR56AG057469 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HOOK, VIVIAN Y. H, IKEZU, TSUNEYA · 2017 to 2017
$833k
NIA NIH HHS R01 AG054672NIA NIH HHS R56 AG057469NIA NIH HHS RF1 AG054199NIGMS NIH HHS T32 GM008541
6 · The paper itself

Abstract

Accumulation of microtubule associated protein tau in the substantia nigra is associated with several tauopathies including progressive supranuclear palsy (PSP). A number of studies have used mutant tau transgenic mouse model to mimic the neuropathology of tauopathies and disease phenotypes. However, tau expression in these transgenic mouse models is not specific to brain subregions, and may not recapitulate subcortical disease phenotypes of PSP. It is necessary to develop a new disease modeling system for cell and region-specific expression of pathogenic tau for modeling PSP in mouse brain. In this study, we developed a novel strategy to express P301L mutant tau to the dopaminergic neurons of substantia nigra by coupling tyrosine hydroxylase promoter Cre-driver mice with a Cre-inducible adeno-associated virus (iAAV). The results showed that P301L mutant tau was successfully transduced in the dopaminergic neurons of the substantia nigra at the presence of Cre recombinase and iAAV. Furthermore, the iAAV-tau-injected mice displayed severe motor deficits including impaired movement ability, motor balance, and motor coordination compared to the control groups over a short time-course. Immunochemical analysis revealed that tau gene transfer significantly resulted in loss of tyrosine hydroxylase-positive dopaminergic neurons and elevated phosphorylated tau in the substantia nigra. Our development of dopaminergic neuron-specific neurodegenerative mouse model with tauopathy will be helpful for studying the underlying mechanism of pathological protein propagation as well as development of new therapies.

Indexed as

DependovirusAnimalsDisease Models, AnimalDopaminergic NeuronsGenetic VectorsIntegrasesMice, TransgenicMotor DisordersMutationNerve DegenerationPhosphorylationSubstantia NigraSupranuclear Palsy, Progressivetau ProteinsTransduction, GeneticTyrosine 3-MonooxygenaseCre recombinaseIntegrasesMAPT protein, humantau ProteinsTyrosine 3-Monooxygenaseadeno-associated virusmicrotubule-associated protein tauneurodegenerative diseasessubstantia nigratauopathies

Identifiers

PMID31689387
PMCPMC6898791
OpenAlexW2984843519

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.